ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2264

Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases

Anna Postolova1 and Mark C. Genovese2, 1Department of Medicine, Stanford University Medical Center, Palo Alto, CA, 2Department of Medicine, Stanford University, Palo Alto, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Inflammation, methotrexate (MTX) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Granulomatous Mastitis is a rare, inflammatory disease of the breast. Presenting symptoms in the breast can be unilateral or bilateral pain, masses, skin induration, erythema, discharge, and abscess formation. Few patients experience self-limited disease over 1-2 years, while most have a longer relapsing course. Imaging modalities such as mammography, ultrasonography, and magnetic resonance imaging (MRI) help characterize lesions, but definitive diagnosis requires histologic examination of tissue via biopsy. Frequently used treatment modalities include antibiotics, prednisone, and surgery, which are often ineffective and fraught with recurrence rates of 50%. This study describes the largest granulomatous mastitis cohort to date in the Americas and Europe with an emphasis on the efficacy of methotrexate treatment.

Methods: Institutional Review Board (IRB) approval was obtained from Stanford University. The Stanford Translational Research Integrated Database Environment (STRIDE) was queried using the terms “granulomatous mastitis” and “rheumatology” and “methotrexate” or “prednisone” from 2006-2017. Inclusion criteria included histopathologically-established granulomatous mastitis patients who were evaluated, treated with methotrexate, and had at least one follow up appointment at the Stanford Immunology and Rheumatology Clinic. Retrospective chart review was performed including pertinent demographic, medical, clinical, and treatment information.

Results: Of the 70 patients identified using STRIDE, 19 met the inclusion criteria. All patients were female with an average age of 33.5 years at the time of presentation. Majority were Hispanic (57.9%), followed by Asian (21.1%), African American (10.5%), and Caucasian (10.5%). The average parity at presentation was 2 children with a latency between the last pregnancy and diagnosis of 29.4 months. Presenting symptoms were unilateral in 68.4% of patients and included breast pain/tenderness (68.4%), mass/lump (47.3%), swelling (21.1%), erythema (21.1%) and induration (15.8%). Most patients had prior unsuccessful treatments with antibiotics (84.2%), incision and drainage (42.1%), prednisone (36.8%), and surgical intervention (5.3%). After three and six months of methotrexate treatment, 89.5% and 94.4% of patients noted disease improvement, respectively. In patients who were compliant with prescribed methotrexate treatment for 12-15 months, 71% achieved disease remission and were disease free on follow up ranging from 1-5 years. The average methotrexate dose in the first 12 months of treatment was 18mg PO weekly. The most common reason for termination of treatment was disease remission.

Conclusion: Our center’s experience demonstrates that granulomatous mastitis presents predominately in multiparous Hispanic females of childbearing age as unilateral, painful breast masses. Methotrexate is an effective treatment modality resulting in sustained disease remission in most patients who are compliant with therapy for at least one year.


Disclosure: A. Postolova, None; M. C. Genovese, None.

To cite this abstract in AMA style:

Postolova A, Genovese MC. Methotrexate in the Treatment of Granulomatous Mastitis: A Retrospective Review of 19 Cases [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/methotrexate-in-the-treatment-of-granulomatous-mastitis-a-retrospective-review-of-19-cases/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-in-the-treatment-of-granulomatous-mastitis-a-retrospective-review-of-19-cases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.